Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRDF Cardiff Oncology	$2.43 -0.6%	$3.43	$2.09 ▼ $5.64	$162.00M	1.54	1.43 million shs	52,727 shs
EDIT Editas Medicine	$2.94 -0.8%	$2.54	$0.91 ▼ $4.19	$263.92M	2.19	2.95 million shs	156,003 shs
RPTX Repare Therapeutics	$1.57 +0.3%	$1.48	$0.89 ▼ $4.07	$67.23M	0.93	314,532 shs	1,148 shs
ZYBT Zhengye Biotechnology	$7.61 -9.4%	$6.32	$3.50 ▼ $14.30	$358.96M	N/A	61,501 shs	21,661 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRDF Cardiff Oncology	-0.41%	+1.24%	-40.78%	-13.17%	+11.93%
EDIT Editas Medicine	-3.90%	+18.88%	+7.64%	+96.03%	-20.86%
RPTX Repare Therapeutics	-1.89%	+2.63%	+9.09%	+16.42%	-44.68%
ZYBT Zhengye Biotechnology	-9.40%	+33.74%	+36.87%	-2.93%	+760,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRDF Cardiff Oncology	2.0681 of 5 stars	3.4	1.0	0.0	0.0	2.3	1.7	0.6
EDIT Editas Medicine	4.3105 of 5 stars	3.2	4.0	0.0	4.3	2.2	2.5	0.6
RPTX Repare Therapeutics	2.8213 of 5 stars	3.3	3.0	0.0	0.0	2.5	2.5	0.6
ZYBT Zhengye Biotechnology	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRDF Cardiff Oncology	2.83	Moderate Buy	$10.10	313.93% Upside
EDIT Editas Medicine	2.31	Hold	$4.90	65.54% Upside
RPTX Repare Therapeutics	2.50	Moderate Buy	$4.50	188.46% Upside
ZYBT Zhengye Biotechnology	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest RPTX, CRDF, EDIT, and ZYBT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	EDIT Editas Medicine	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$4.00 ➝ $6.00
8/6/2025	CRDF Cardiff Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$18.00 ➝ $10.00
7/8/2025	CRDF Cardiff Oncology	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$19.00
6/24/2025	CRDF Cardiff Oncology	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold	$3.50
6/18/2025	CRDF Cardiff Oncology	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRDF Cardiff Oncology	$680K	238.73	N/A	N/A	$0.88 per share	2.77
EDIT Editas Medicine	$32.31M	8.24	N/A	N/A	$0.21 per share	14.10
RPTX Repare Therapeutics	$53.48M	1.25	N/A	N/A	$2.57 per share	0.61
ZYBT Zhengye Biotechnology	$25.53M	14.06	$0.09 per share	81.52	$1.02 per share	7.46

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRDF Cardiff Oncology	-$45.43M	-$0.87	N/A	N/A	N/A	-9,344.14%	-77.94%	-63.65%	N/A
EDIT Editas Medicine	-$237.09M	-$3.04	N/A	N/A	N/A	-608.88%	-200.25%	-68.57%	11/3/2025 (Estimated)
RPTX Repare Therapeutics	-$84.69M	-$2.58	N/A	N/A	N/A	N/A	-78.25%	-66.85%	N/A
ZYBT Zhengye Biotechnology	$1.55M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest RPTX, CRDF, EDIT, and ZYBT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	EDIT Editas Medicine	-$0.41	-$0.63	-$0.22	-$0.63	$1.81 million	$3.58 million
8/8/2025	Q2 2025	RPTX Repare Therapeutics	-$0.56	-$0.39	+$0.17	-$0.39	$2.50 million	$0.25 million
7/29/2025	Q2 2025	CRDF Cardiff Oncology	-$0.19	-$0.21	-$0.02	-$0.21	$0.11 million	$0.12 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRDF Cardiff Oncology	N/A	N/A	N/A	N/A	N/A
EDIT Editas Medicine	N/A	N/A	N/A	N/A	N/A
RPTX Repare Therapeutics	N/A	N/A	N/A	N/A	N/A
ZYBT Zhengye Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRDF Cardiff Oncology	N/A	4.42	4.42
EDIT Editas Medicine	N/A	2.77	3.08
RPTX Repare Therapeutics	N/A	6.30	7.42
ZYBT Zhengye Biotechnology	0.01	1.31	0.88

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRDF Cardiff Oncology	16.29%
EDIT Editas Medicine	71.90%
RPTX Repare Therapeutics	85.09%
ZYBT Zhengye Biotechnology	N/A

Insider Ownership

Company	Insider Ownership
CRDF Cardiff Oncology	7.70%
EDIT Editas Medicine	2.10%
RPTX Repare Therapeutics	11.50%
ZYBT Zhengye Biotechnology	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRDF Cardiff Oncology	20	66.53 million	61.40 million	Optionable
EDIT Editas Medicine	230	89.92 million	81.96 million	Optionable
RPTX Repare Therapeutics	180	42.96 million	38.02 million	Optionable
ZYBT Zhengye Biotechnology	278	47.17 million	N/A	N/A

RPTX, CRDF, EDIT, and ZYBT Headlines

Recent News About These Companies

Zhengye Biotechnology (NASDAQ:ZYBT) Raised to Hold at Wall Street Zen

August 2, 2025 | marketbeat.com

ZYBT | Zhengye Biotechnology Holding Ltd. Company Profile & Executives ...

July 17, 2025 | wsj.com

Zhengye Biotechnology Holding Limited Announces Fiscal Year 2024 Financial Results | ZYBT Stock News

July 3, 2025 | gurufocus.com

Zhengye Biotechnology Holding Limited Announces Fiscal Year 2024 Financial Results

July 3, 2025 | prnewswire.com

ZYBT | Zhengye Biotechnology Holding Ltd. Stock Overview (U.S.: Nasdaq) - Barron's

July 2, 2025 | barrons.com

ZYBT - Zhengye Biotechnology Holding Ltd Chart - Morningstar

June 27, 2025 | morningstar.comM

Zhengye Biotechnology Holding Ltd

June 21, 2025 | morningstar.comM

ZYBT Zhengye Biotechnology Holding Limited

May 30, 2025 | seekingalpha.com

Zhengye Biotechnology faces NASDAQ compliance issue

May 24, 2025 | investing.com

Zhengye Biotechnology Holding Limited Receives NASDAQ Delinquency Letter for Non-Compliance with Listing Requirements

May 23, 2025 | quiverquant.comQ

Zhengye Biotechnology Holding Limited Receives NASDAQ Notice Related to Late Filing of Form 20-F

May 23, 2025 | globenewswire.com

Should We Be Cautious About Zhengye Biotechnology Holding Limited's (NASDAQ:ZYBT) ROE Of 6.9%?

April 7, 2025 | finance.yahoo.com

Zhengye Biotechnology Holding Ltd.

April 3, 2025 | wsj.com

Zhengye Biotechnology Holding Limited (ZYBT)

March 27, 2025 | finance.yahoo.com

Zhengye Biotechnology Holding Limited Announces Full Exercise of Underwriters' Over-Allotment Option

January 14, 2025 | globenewswire.com

Zhengye Biotechnology Holding Limited Announces Closing of Initial Public Offering

January 8, 2025 | globenewswire.com

Zhengye Biotechnology Holding Limited Announces Pricing of Initial Public Offering

January 6, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

RPTX, CRDF, EDIT, and ZYBT Company Descriptions

Cardiff Oncology NASDAQ:CRDF

$2.42 -0.02 (-0.61%)

As of 09:51 AM Eastern

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Editas Medicine NASDAQ:EDIT

$2.94 -0.03 (-0.84%)

As of 09:51 AM Eastern

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Repare Therapeutics NASDAQ:RPTX

$1.56 +0.01 (+0.32%)

As of 09:50 AM Eastern

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase 1 clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.

Zhengye Biotechnology NASDAQ:ZYBT

$7.61 -0.79 (-9.40%)

As of 08/14/2025 03:21 PM Eastern

Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time